ConductScience.org, home

Paper41014398

Do the therapeutic vaccines hold hope for the treatment of hepatitis B?

Yan Q and 3 others. Hepatol Int, 2025. Cited by 8 papers, by iCite.

Cite this record

ConductScience Library. Do the therapeutic vaccines hold hope for the treatment of hepatitis B? Papers, record 41014398. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41014398

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Do the therapeutic vaccines hold hope for the treatment of hepatitis B?
PubMed
Journal
Hepatol Int
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
8
iCite
Relative citation ratio, by iCite
2.09, provisional
iCite
Revised in PubMed
2025-12-21
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yan QQiujing
2Fu XXinghuan
3Wang YYanhttps://orcid.org/0000-0002-8577-0527
4Wang GGuiqianghttps://orcid.org/0000-0002-0317-7536

Source PubMed

Download CSV of authors

Topics5

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Hepatitis B, ChronicMajor topic
Hepatitis B VaccinesMajor topic
Humans
Antiviral Agents
Hepatitis B virus

Grants7

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
82270626National Natural Science Foundation of ChinaPubMed
81870417National Natural Science Foundation of ChinaPubMed
82070605National Natural Science Foundation of ChinaPubMed
2022CR63Peking University First HospitalPubMed
2025SF052Peking University First HospitalPubMed
2020A03004-3Science and Technology Department of Xinjiang Uygur Autonomous RegionPubMed
2024-zz-102Beijing postdoctoral research activities innovation research and development fundPubMed

Source PubMed

Download CSV of grants

References42

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
119697028Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients.Ann Hematol2010https://conductscience.org/library/papers/19697028PubMed
234661089Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study.JHEP Rep2021https://conductscience.org/library/papers/34661089PubMed
334629819Treatment of hepatitis B virus infection in children and adolescents.World J Gastroenterol2021https://conductscience.org/library/papers/34629819PubMed
428735813Atypical memory B cells in human chronic infectious diseases: An interim report.Cell Immunol2017https://conductscience.org/library/papers/28735813PubMed
524555998Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial--ANRS HB02 VAC-ADN.Gut2015https://conductscience.org/library/papers/24555998PubMed
625858855Hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis B infection.Vaccine2015https://conductscience.org/library/papers/25858855PubMed
725045824Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study.Vaccine2014https://conductscience.org/library/papers/25045824PubMed
830133478Treatment of chronic hepatitis B naïve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial).PLoS One2018https://conductscience.org/library/papers/30133478PubMed
930982722Hepatitis B virus infection in children and adolescents.Lancet Gastroenterol Hepatol2019https://conductscience.org/library/papers/30982722PubMed
1022884884
Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.
Antiviral Res2012https://conductscience.org/library/papers/22884884PubMed
1134804072Pegylated Interferon Treatment for the Effective Clearance of Hepatitis B Surface Antigen in Inactive HBsAg Carriers: A Meta-Analysis.Front Immunol2021https://conductscience.org/library/papers/34804072PubMed
1211244031Noncytolytic control of viral infections by the innate and adaptive immune response.Annu Rev Immunol2001https://conductscience.org/library/papers/11244031PubMed
1326058465Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival.Chin J Cancer2015https://conductscience.org/library/papers/26058465PubMed
1428127204Phase IIb trial of in vivo electroporation mediated dual-plasmid hepatitis B virus DNA vaccine in chronic hepatitis B patients under lamivudine therapy.World J Gastroenterol2017https://conductscience.org/library/papers/28127204PubMed
1538808361Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting.Clin Mol Hepatol2024https://conductscience.org/library/papers/38808361PubMed
1636851208HBV and HCV Infection in Children and Adolescents.Vaccines (Basel)2023https://conductscience.org/library/papers/36851208PubMed
1737243066Antiviral Response across Genotypes after Treatment of Chronic Hepatitis B Patients with the Therapeutic Vaccine NASVAC or Pegylated Interferon.Vaccines (Basel)2023https://conductscience.org/library/papers/37243066PubMed
1830930022Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis.Gastroenterology2019https://conductscience.org/library/papers/30930022PubMed
1918031872Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine.Vaccine2007https://conductscience.org/library/papers/18031872PubMed
2037791379HBV001: Phase I study evaluating the safety and immunogenicity of the therapeutic vaccine ChAdOx1-HBV.JHEP Rep2023https://conductscience.org/library/papers/37791379PubMed

See all 42 referencesDownload CSV of references

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.

PMIDTitleJournalYearIn PapersSource
42931375Assessing the Status of and Impediments to Achieving the WHO Goal to Eliminate Viral Hepatitis B by 2030: A Scoping Review.Vaccines (Basel)2026https://conductscience.org/library/papers/42931375PubMed
42829048Combining antiviral therapy with cancer treatment in HBV-associated HCC: A translational approach.Virus Res2026https://conductscience.org/library/papers/42829048PubMed
42769254FBXO11 and FBXO32 are associated with TRAF3-TBK1-IRF3 signaling components in chronic hepatitis B: evidence from clinical samples and preliminary mechanistic studies.Am J Transl Res2026https://conductscience.org/library/papers/42769254PubMed
42506615Advancing Global Hepatitis B Elimination: The Case for Using Maize as a Low-Cost, Heat-Stable, and Scalable Oral Vaccine.Vaccines (Basel)2026https://conductscience.org/library/papers/42506615PubMed
42347630Therapeutic Vaccines for Chronic Viral Infections: From Immune Modulation to Clinical Translation.Vaccines (Basel)2026https://conductscience.org/library/papers/42347630PubMed
42328176Beyond viral suppression: combining PEG-interferon with novel immunotherapies for functional cure of chronic hepatitis B.Front Cell Infect Microbiol2026https://conductscience.org/library/papers/42328176PubMed
41828677Accuracy of Diagnostic Investigations in Monitoring Hepatitis B Virus Infection: Strengths, Limitations, and Emerging Biomarkers.Int J Mol Sci2026https://conductscience.org/library/papers/41828677PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41014398

GET https://conductscience.org/api/papers/v1/41014398/references?page=2